Skip to main content
. 2020 Jun 17;15(6):e0232371. doi: 10.1371/journal.pone.0232371

Table 3. Patients overall survival and subgroup analysis.

Overall Survival
n 1yr 2yrs 3yrs 4yrs 5yrs
PATIENTS 101 58 32 23 16
71% 41% 22% 16% 11%
Sarcopenic 121 83 47 26 20 14
69% 39% 21% 17% 12%
Non-sarcopenic 21 18 11 6 3 2
86% 52% 29% 14% 10%